Skip to main content

Resultados relacionados

Resultados totales (Incluyendo duplicados): 12
Encontrada(s) 1 página(s)

Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

Identification of ZBTB18 as a novel colorectal tumor suppressor gene through genome-wide promoter hypermethylation analysis

  • Bazzocco, Sarah
  • Dopeso Gonzalez, J Higinio
  • Martinez Barriocanal, Agueda
  • Li, Jing
  • Garcia Vidal, Elia Maria
  • Maggio, Valentina
  • Gonçalves Rodrigues, Paulo Andre
  • Guimaraes De Marcondes, Priscila
  • Schwartz Navarro, Simon
  • Arango Corro, Diego
  • Anguita Espinosa, Estefanía
  • Nieto Raya, Rocio
Càncer colorectal; Metilació; Dit de zinc, Cáncer colorrectal; Metilación; Dedo de zinc, Colorectal cancer; Methylation; Zinc finger, Background Cancer initiation and progression are driven by genetic and epigenetic changes. Although genome/exome sequencing has significantly contributed to the characterization of the genetic driver alterations, further investigation is required to systematically identify cancer driver genes regulated by promoter hypermethylation. Results Using genome-wide analysis of promoter methylation in 45 colorectal cancer cell lines, we found that higher overall methylation levels were associated with microsatellite instability (MSI), faster proliferation and absence of APC mutations. Because epigenetically silenced genes could represent important oncogenic drivers, we used mRNA expression profiling of colorectal cancer cell lines and primary tumors to identify a subset of 382 (3.9%) genes for which promoter methylation was negatively associated with gene expression. Remarkably, a significant enrichment in zinc finger proteins was observed, including the transcriptional repressor ZBTB18. Re-introduction of ZBTB18 in colon cancer cells significantly reduced proliferation in vitro and in a subcutaneous xenograft mouse model. Moreover, immunohistochemical analysis revealed that ZBTB18 is frequently lost or reduced in colorectal tumors, and reduced ZBTB18 expression was found to be associated with lymph node metastasis and shorter survival of patients with locally advanced colorectal cancer. Conclusions We identified a set of 382 genes putatively silenced by promoter methylation in colorectal cancer that could significantly contribute to the oncogenic process. Moreover, as a proof of concept, we demonstrate that the epigenetically silenced gene ZBTB18 has tumor suppressor activity and is a novel prognostic marker for patients with locally advanced colorectal cancer., This study was partially funded by grants of the Instituto de Salud Carlos III and the European Regional Development Fund (ERDF; PI16/00540, PI19/00993, AC20/00022 and AC15/00066) and the Spanish Association Against Cancer (AECC GCA15152966ARAN) to Diego Arango.
Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

Loss of MYO5B expression deregulates late endosome size which hinders mitotic spindle orientation

  • Leng, Changsen
  • Carton García, Fernando
  • Li, Qinghong
  • Klappe, Karin
  • Kuipers, Jeroen
  • Arango Corro, Diego
  • Overeem, Arend W.
MYO5B; Epithelial architecture; Recycling endosomes, MYO5B; Arquitectura epitelial; Reciclaje de endosomas, MYO5B; Arquitectura epitelial; Reciclatge d'endosomes, Recycling endosomes regulate plasma membrane recycling. Recently, recycling endosome–associated proteins have been implicated in the positioning and orientation of the mitotic spindle and cytokinesis. Loss of MYO5B, encoding the recycling endosome–associated myosin Vb, is associated with tumor development and tissue architecture defects in the gastrointestinal tract. Whether loss of MYO5B expression affects mitosis is not known. Here, we demonstrate that loss of MYO5B expression delayed cytokinesis, perturbed mitotic spindle orientation, led to the misorientation of the plane of cell division during the course of mitosis, and resulted in the delamination of epithelial cells. Remarkably, the effects on spindle orientation, but not cytokinesis, were a direct consequence of physical hindrance by giant late endosomes, which were formed in a chloride channel–sensitive manner concomitant with a redistribution of chloride channels from the cell periphery to late endosomes upon loss of MYO5B. Rab7 availability was identified as a limiting factor for the development of giant late endosomes. In accordance, increasing rab7 availability corrected mitotic spindle misorientation and cell delamination in cells lacking MYO5B expression. In conclusion, we identified a novel role for MYO5B in the regulation of late endosome size control and identify the inability to control late endosome size as an unexpected novel mechanism underlying defects in cell division orientation and epithelial architecture., AD: Association for International Cancer Research (AICR13-0245), https://www.aicr.org AD: European Regional Development Fund (ERDF; PI16/00540 and AC15/00066), https://ec.europa.eu/regional_policy/en/funding/erdf AD: Spanish Association Against Cancer (AECC GCA15152966ARAN), https://www.uicc.org AD: the Instituto de Salud Carlos III, https://www.isciii.es/Paginas/Inicio.aspx IZ: The Dutch Research Council, Domain Applied and Engineering Sciences, https://www.nwo.nl/en JK: The Netherlands Organisation for Health Research and Development, 91111.006, https://www.zonmw.nl/en/ JK: The Dutch Research Council, 175-010-2009-023, https://www.nwo.nl/en CK: Chinese Scholarship Council, https://www.chinesescholarshipcouncil.com/ QL: Chinese Scholarship Council, https://www.chinesescholarshipcouncil.com/ YC: Chinese Scholarship Council, https://www.chinesescholarshipcouncil.com/
Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

Tumor expression of cyclin-dependent kinase 5 (Cdk5) is a prognostic biomarker and predicts outcome of oxaliplatin-treated metastatic colorectal cancer patients

  • Ruiz de Porras, Vicenç
  • Bystrup, Sara
  • Cabrero-de Las Heras, Sara
  • Musulén, Eva
  • Palomero, Luis
  • Henar Alonso, Maria
  • Arango Corro, Diego
  • Nieto Raya, Rocio
Colorectal cancer; Cyclin-dependent kinase 5 (Cdk5); Prognostic and predictive biomarker, Cáncer colorrectal; Quinasa dependiente de ciclina 5 (Cdk5); Biomarcador pronóstico y predictivo, Càncer colorectal; Quinasa dependent de ciclina 5 (CDK5); Biomarcador pronòstic i predictiu, In recent years, an increasing number of studies have shown that elevated expression of cyclin dependent kinase (Cdk5) contributes to the oncogenic initiation and progression of many types of cancers. In this study, we investigated the expression pattern of Cdk5 in colorectal cancer (CRC) cell lines and in a large number of tumor samples in order to evaluate its relevance in this pathogenesis and possible use as a prognostic marker. We found that Cdk5 is highly expressed and activated in CRC cell lines and that silencing of the kinase decreases their migration ability. In tumor tissues, Cdk5 is overexpressed compared to normal tissues due to a copy number gain. In patients with localized disease, we found that high Cdk5 levels correlate with poor prognosis, while in the metastatic setting, this was only the case for patients receiving an oxaliplatin-based treatment. When exploring the Cdk5 levels in the consensus molecular subtypes (CMS), we found the lowest levels in subtype 1, where high Cdk5 again was associated with a poorer prognosis. In conclusion, we confirm that Cdk5 is involved in CRC and disease progression and that it could serve as a prognostic and predictive biomarker in this disease., This work has been funded by the ISCIII grants from the Spanish Government, project numbers PI09/01334 and PI12/02228, and the Departament d’Innovació, Universitats i Empresa, Generalitat de Catalunya, project numbers 2014-SGR-1494, 2017-SGR-1705 and 2017-SGR-723. The group from Eva Martinez Balibrea is furthermore funded by the PIE16/00011 and the group from Diego Arango by the PI16/00540 and AC15/00066 grants.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Mechanisms of inactivation of the tumour suppressor gene RHOA in colorectal cancer

  • Dopeso, Higinio|||0000-0003-0060-1861
  • Rodrigues, Paulo|||0000-0002-5380-2715
  • Bilic Zimmermann, Josipa|||0000-0001-9642-6265
  • Bazzocco, Sarah
  • Cartón-Garcia, Fernando|||0000-0002-1858-6551
  • Macaya, Irati|||0000-0001-5698-6452
  • de Marcondes, Priscila Guimarães|||0000-0001-7271-2881
  • Anguita, Estefanía|||0000-0003-2230-7030
  • Masanas, Marc|||0000-0002-2249-8554
  • Jiménez-Flores, Lizbeth M.
  • Martínez-Barriocanal, Águeda|||0000-0002-8809-160X
  • Nieto Raya, Rocio|||0000-0001-8567-2268
  • Segura, Miguel F.|||0000-0003-0916-3618
  • Schwartz, Simon|||0000-0001-8297-7971
  • Mariadason, John M.|||0000-0001-9123-7684
  • Arango, Diego|||0000-0003-2953-3284
Reduced RHOA signalling has been shown to increase the growth/metastatic potential of colorectal tumours. However, the mechanisms of inactivation of RHOA signalling in colon cancer have not been characterised. A panel of colorectal cancer cell lines and large cohorts of primary tumours were used to investigate the expression and activity of RHOA, as well as the presence of RHOA mutations/deletions and promoter methylation affecting RHOA. Changes in RHOA expression were assessed by western blotting and qPCR after modulation of microRNAs, SMAD4 and c-MYC. We show here that RHOA point mutations and promoter hypermethylation do not significantly contribute to the large variability of RHOA expression observed among colorectal tumours. However, RHOA copy number loss was observed in 16% of colorectal tumours and this was associated with reduced RHOA expression. Moreover, we show that miR-200a/b/429 downregulates RHOA in colorectal cancer cells. In addition, we found that TGF- β /SMAD4 upregulates the RHOA promoter. Conversely, RHOA expression is transcriptionally downregulated by canonical Wnt signalling through the Wnt target gene c-MYC that interferes with the binding of SP1 to the RHOA promoter in colon cancer cells. We demonstrate a complex pattern of inactivation of the tumour suppressor gene RHOA in colon cancer cells through genetic, transcriptional and post-transcriptional mechanisms.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Tumor expression of cyclin-dependent kinase 5 (Cdk5) is a prognostic biomarker and predicts outcome of oxaliplatin-treated metastatic colorectal cancer patients

  • Ruiz de Porras, Vicenç|||0000-0002-4352-1784
  • Bystrup, Sara|||0000-0002-7971-0851
  • Cabrero de las Heras, Sara
  • Musulén, Eva|||0000-0002-9667-6464
  • Palomero, Luis|||0000-0002-9144-1017
  • Alonso, María Henar
  • Nieto Raya, Rocio|||0000-0001-8567-2268
  • Arango, Diego|||0000-0003-2953-3284
  • Moreno Aguado, Victor Raul|||0000-0002-2818-5487
  • Queralt, C.|||0000-0001-9875-0173
  • Manzano Mozo, José Luís
  • Layos, Laura
  • Bugés, Cristina|||0000-0003-2013-1510
  • Martínez Balibrea, Eva|||0000-0002-4501-7100
In recent years, an increasing number of studies have shown that elevated expression of cyclin dependent kinase (Cdk5) contributes to the oncogenic initiation and progression of many types of cancers. In this study, we investigated the expression pattern of Cdk5 in colorectal cancer (CRC) cell lines and in a large number of tumor samples in order to evaluate its relevance in this pathogenesis and possible use as a prognostic marker. We found that Cdk5 is highly expressed and activated in CRC cell lines and that silencing of the kinase decreases their migration ability. In tumor tissues, Cdk5 is overexpressed compared to normal tissues due to a copy number gain. In patients with localized disease, we found that high Cdk5 levels correlate with poor prognosis, while in the metastatic setting, this was only the case for patients receiving an oxaliplatin-based treatment. When exploring the Cdk5 levels in the consensus molecular subtypes (CMS), we found the lowest levels in subtype 1, where high Cdk5 again was associated with a poorer prognosis. In conclusion, we confirm that Cdk5 is involved in CRC and disease progression and that it could serve as a prognostic and predictive biomarker in this disease.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Silencing of adaptor protein 32 reduces / receptors expression and impairs gastrointestinal stromal tumors growth

  • Serrano-Candelas, Eva
  • Ainsua-Enrich, Erola|||0000-0001-7901-5798
  • Navinés-Ferrer, Arnau
  • Rodrigues, Paulo|||0000-0002-5380-2715
  • García-Valverde, Alfonso|||0000-0002-5616-3082
  • Bazzocco, Sarah
  • Macaya, Irati|||0000-0001-5698-6452
  • Arribas, Joaquín V.|||0000-0002-0504-0664
  • Serrano, Cesar|||0000-0003-1416-8739
  • Sayós, Joan|||0000-0002-4664-3461
  • Arango, Diego|||0000-0003-2953-3284
  • Martin, Margarita
Gastrointestinal stromal tumors (s) represent about 80% of the mesenchymal neoplasms of the gastrointestinal tract. Most s contain oncogenic (85%) or (5%) receptors. The kinase inhibitor imatinib mesylate is the preferential treatment for these tumors; however, the development of drug resistance has highlighted the need for novel therapeutic strategies. Recently, we reported that the adaptor molecule 3 Binding Protein 2 (32) regulates expression and signaling in human mast cells. Our current study shows that 32 is expressed in primary tumors and cell lines from patients and that 32 silencing leads to a downregulation of oncogenic and expression and an increase in apoptosis in imatinib-sensitive and imatinib-resistant cells. The microphthalmia-associated transcription factor (), involved in expression in mast cells and melanocytes, is expressed in s. Interestingly, is reduced after 32 silencing. Importantly, reconstitution of both 32 and restores cell viability. Furthermore, 32 silencing significantly reduces cell migration and tumor growth of imatinib-sensitive and imatinib-resistant cells in vivo. Altogether, 32 regulates and expression and cell viability, indicating a role as a potential target in imatinib-sensitive and imatinib-resistant s.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Investigation of the role of tyrosine kinase receptor EPHA3 in colorectal cancer

  • Andretta, Elena
  • Cartón-Garcia, Fernando|||0000-0002-1858-6551
  • Martínez-Barriocanal, Águeda|||0000-0002-8809-160X
  • de Marcondes, Priscila Guimarães|||0000-0001-7271-2881
  • Jimenez-Flores, Lizbeth M.
  • Macaya, Irati|||0000-0001-5698-6452
  • Bazzocco, Sarah
  • Bilic Zimmermann, Josipa|||0000-0001-9642-6265
  • Rodrigues, Paulo|||0000-0002-5380-2715
  • Nieto Raya, Rocio|||0000-0001-8567-2268
  • Landolfi, Stefania|||0000-0002-1059-635X
  • Ramón y Cajal, Santiago|||0000-0002-3867-1390
  • Schwartz, Simon|||0000-0001-8297-7971
  • Brown, Arthur
  • Dopeso, Higinio|||0000-0003-0060-1861
  • Arango, Diego|||0000-0003-2953-3284
EPH signaling deregulation has been shown to be important for colorectal carcinogenesis and genome-wide sequencing efforts have identified EPHA3 as one of the most frequently mutated genes in these tumors. However, the role of EPHA3 in colorectal cancer has not been thoroughly investigated. We show here that ectopic expression of wild type EPHA3 in colon cancer cells did not affect their growth, motility/invasion or metastatic potential in vivo. Moreover, overexpression of mutant EPHA3 or deletion of the endogenous mutant EPHA3 in colon cancer cells did not affect their growth or motility. EPHA3 inactivation in mice did not initiate the tumorigenic process in their intestine, and had no effects on tumor size/multiplicity after tumor initiation either genetically or pharmacologically. In addition, immunohistochemical analysis of EPHA3 tumor levels did not reveal associations with survival or clinicopathological features of colorectal cancer patients. In conclusion, we show that EPHA3 does not play a major role in colorectal tumorigenesis. These results significantly contribute to our understanding of the role of EPH signaling during colorectal carcinogenesis, and highlighting the need for detailed functional studies to confirm the relevance of putative cancer driver genes identified in sequencing efforts of the cancer genome.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Loss of the EPH receptor B6 contributes to colorectal cancer metastasis

  • Mateo-Lozano, Silvia
  • Bazzocco, Sarah
  • Rodrigues, Paulo|||0000-0002-5380-2715
  • Mazzolini, Rocco|||0000-0003-3249-8387
  • Andretta, Elena
  • Dopeso, Higinio|||0000-0003-0060-1861
  • Fernández Caparrós, Yolanda
  • del Llano, Edgar
  • Bilic Zimmermann, Josipa|||0000-0001-9642-6265
  • Suárez-López, Lucía
  • Macaya, Irati|||0000-0001-5698-6452
  • Cartón-Garcia, Fernando|||0000-0002-1858-6551
  • Nieto Raya, Rocio|||0000-0001-8567-2268
  • Jimenez-Flores, Lizbeth M.
  • de Marcondes, Priscila Guimarães|||0000-0001-7271-2881
  • Núñez, Yáiza|||0000-0001-7268-2125
  • Afonso, Elsa
  • Cacci, Karina
  • Hernandez-Losa, Javier|||0000-0003-1526-3201
  • Landolfi, Stefania|||0000-0002-1059-635X
  • Abasolo, Ibane|||0000-0001-5970-6276
  • Ramón y Cajal, Santiago|||0000-0002-3867-1390
  • Mariadason, John M.|||0000-0001-9123-7684
  • Schwartz, Simon|||0000-0001-8297-7971
  • Matsui, Toshimitsu
  • Arango, Diego|||0000-0003-2953-3284
Although deregulation of EPHB signaling has been shown to be an important step in colorectal tumorigenesis, the role of EPHB6 in this process has not been investigated. We found here that manipulation of EPHB6 levels in colon cancer cell lines has no effect on their motility and growth on a solid substrate, soft agar or in a xenograft mouse model. We then used an EphB6 knockout mouse model to show that EphB6 inactivation does not efficiently initiate tumorigenesis in the intestinal tract. In addition, when intestinal tumors are initiated genetically or pharmacologically in EphB6 +/+ and EphB6 -/- mice, no differences were observed in animal survival, tumor multiplicity, size or histology, and proliferation of intestinal epithelial cells or tumor cells. However, reintroduction of EPHB6 into colon cancer cells significantly reduced the number of lung metastasis after tail-vein injection in immunodeficient mice, while EPHB6 knockdown in EPHB6-expressing cells increased their metastatic spread. Consistently, although EPHB6 protein expression in a series of 130 primary colorectal tumors was not associated with patient survival, EPHB6 expression was significantly lower in lymph node metastases compared to primary tumors. Our results indicate that the loss of EPHB6 contributes to the metastatic process of colorectal cancer.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Identification of ZBTB18 as a novel colorectal tumor suppressor gene through genome-wide promoter hypermethylation analysis

  • Bazzocco, Sarah
  • Dopeso, Higinio|||0000-0003-0060-1861
  • Martínez-Barriocanal, Águeda|||0000-0002-8809-160X
  • Anguita, Estefanía|||0000-0003-2230-7030
  • Nieto Raya, Rocio|||0000-0001-8567-2268
  • Li, Jing|||0000-0002-9283-3821
  • Garcia-Vidal, Elia|||0000-0002-2756-9438
  • Maggio, Valentina|||0000-0002-4985-5611
  • Rodrigues, Paulo|||0000-0002-5380-2715
  • de Marcondes, Priscila Guimarães|||0000-0001-7271-2881
  • Schwartz, Simon|||0000-0001-8297-7971
  • Aaltonen, Lauri A.|||0000-0001-6839-4286
  • Sánchez, Alex|||0000-0002-8673-7737
  • Mariadason, John M.|||0000-0001-9123-7684
  • Arango, Diego|||0000-0003-2953-3284
Cancer initiation and progression are driven by genetic and epigenetic changes. Although genome/exome sequencing has significantly contributed to the characterization of the genetic driver alterations, further investigation is required to systematically identify cancer driver genes regulated by promoter hypermethylation. Using genome-wide analysis of promoter methylation in 45 colorectal cancer cell lines, we found that higher overall methylation levels were associated with microsatellite instability (MSI), faster proliferation and absence of APC mutations. Because epigenetically silenced genes could represent important oncogenic drivers, we used mRNA expression profiling of colorectal cancer cell lines and primary tumors to identify a subset of 382 (3.9%) genes for which promoter methylation was negatively associated with gene expression. Remarkably, a significant enrichment in zinc finger proteins was observed, including the transcriptional repressor ZBTB18. Re-introduction of ZBTB18 in colon cancer cells significantly reduced proliferation in vitro and in a subcutaneous xenograft mouse model. Moreover, immunohistochemical analysis revealed that ZBTB18 is frequently lost or reduced in colorectal tumors, and reduced ZBTB18 expression was found to be associated with lymph node metastasis and shorter survival of patients with locally advanced colorectal cancer. We identified a set of 382 genes putatively silenced by promoter methylation in colorectal cancer that could significantly contribute to the oncogenic process. Moreover, as a proof of concept, we demonstrate that the epigenetically silenced gene ZBTB18 has tumor suppressor activity and is a novel prognostic marker for patients with locally advanced colorectal cancer. The online version contains supplementary material available at 10.1186/s13148-021-01070-0.
Scientia. Dipòsit d'Informació Digital del Departament de Salut
Publication Artículo científico (JournalArticle)

Identification of ZBTB18 as a novel colorectal tumor suppressor gene through genome-wide promoter hypermethylation analysis

  • Bazzocco, Sarah
  • Dopeso Gonzalez, J Higinio
  • Martinez Barriocanal, Agueda
  • Li, Jing
  • Garcia Vidal, Elia Maria
  • Maggio, Valentina
  • Gonçalves Rodrigues, Paulo Andre
  • Guimaraes De Marcondes, Priscila
  • Schwartz Navarro, Simon
  • Arango Corro, Diego
  • Anguita Espinosa, Estefanía
  • Nieto Raya, Rocio
Càncer colorectal; Metilació; Dit de zinc, Cáncer colorrectal; Metilación; Dedo de zinc, Colorectal cancer; Methylation; Zinc finger, Background Cancer initiation and progression are driven by genetic and epigenetic changes. Although genome/exome sequencing has significantly contributed to the characterization of the genetic driver alterations, further investigation is required to systematically identify cancer driver genes regulated by promoter hypermethylation. Results Using genome-wide analysis of promoter methylation in 45 colorectal cancer cell lines, we found that higher overall methylation levels were associated with microsatellite instability (MSI), faster proliferation and absence of APC mutations. Because epigenetically silenced genes could represent important oncogenic drivers, we used mRNA expression profiling of colorectal cancer cell lines and primary tumors to identify a subset of 382 (3.9%) genes for which promoter methylation was negatively associated with gene expression. Remarkably, a significant enrichment in zinc finger proteins was observed, including the transcriptional repressor ZBTB18. Re-introduction of ZBTB18 in colon cancer cells significantly reduced proliferation in vitro and in a subcutaneous xenograft mouse model. Moreover, immunohistochemical analysis revealed that ZBTB18 is frequently lost or reduced in colorectal tumors, and reduced ZBTB18 expression was found to be associated with lymph node metastasis and shorter survival of patients with locally advanced colorectal cancer. Conclusions We identified a set of 382 genes putatively silenced by promoter methylation in colorectal cancer that could significantly contribute to the oncogenic process. Moreover, as a proof of concept, we demonstrate that the epigenetically silenced gene ZBTB18 has tumor suppressor activity and is a novel prognostic marker for patients with locally advanced colorectal cancer., This study was partially funded by grants of the Instituto de Salud Carlos III and the European Regional Development Fund (ERDF; PI16/00540, PI19/00993, AC20/00022 and AC15/00066) and the Spanish Association Against Cancer (AECC GCA15152966ARAN) to Diego Arango.
Scientia. Dipòsit d'Informació Digital del Departament de Salut
Publication Artículo científico (JournalArticle)

Tumor expression of cyclin-dependent kinase 5 (Cdk5) is a prognostic biomarker and predicts outcome of oxaliplatin-treated metastatic colorectal cancer patients

  • Ruiz de Porras, Vicenç
  • Bystrup, Sara
  • Cabrero-de Las Heras, Sara
  • Musulén, Eva
  • Palomero, Luis
  • Henar Alonso, Maria
  • Arango Corro, Diego
  • Nieto Raya, Rocio
Colorectal cancer; Cyclin-dependent kinase 5 (Cdk5); Prognostic and predictive biomarker, Cáncer colorrectal; Quinasa dependiente de ciclina 5 (Cdk5); Biomarcador pronóstico y predictivo, Càncer colorectal; Quinasa dependent de ciclina 5 (CDK5); Biomarcador pronòstic i predictiu, In recent years, an increasing number of studies have shown that elevated expression of cyclin dependent kinase (Cdk5) contributes to the oncogenic initiation and progression of many types of cancers. In this study, we investigated the expression pattern of Cdk5 in colorectal cancer (CRC) cell lines and in a large number of tumor samples in order to evaluate its relevance in this pathogenesis and possible use as a prognostic marker. We found that Cdk5 is highly expressed and activated in CRC cell lines and that silencing of the kinase decreases their migration ability. In tumor tissues, Cdk5 is overexpressed compared to normal tissues due to a copy number gain. In patients with localized disease, we found that high Cdk5 levels correlate with poor prognosis, while in the metastatic setting, this was only the case for patients receiving an oxaliplatin-based treatment. When exploring the Cdk5 levels in the consensus molecular subtypes (CMS), we found the lowest levels in subtype 1, where high Cdk5 again was associated with a poorer prognosis. In conclusion, we confirm that Cdk5 is involved in CRC and disease progression and that it could serve as a prognostic and predictive biomarker in this disease., This work has been funded by the ISCIII grants from the Spanish Government, project numbers PI09/01334 and PI12/02228, and the Departament d’Innovació, Universitats i Empresa, Generalitat de Catalunya, project numbers 2014-SGR-1494, 2017-SGR-1705 and 2017-SGR-723. The group from Eva Martinez Balibrea is furthermore funded by the PIE16/00011 and the group from Diego Arango by the PI16/00540 and AC15/00066 grants.
Scientia. Dipòsit d'Informació Digital del Departament de Salut
Publication Artículo científico (JournalArticle)

Loss of MYO5B expression deregulates late endosome size which hinders mitotic spindle orientation

  • Leng, Changsen
  • Carton García, Fernando
  • Li, Qinghong
  • Klappe, Karin
  • Kuipers, Jeroen
  • Arango Corro, Diego
  • Overeem, Arend W.
MYO5B; Epithelial architecture; Recycling endosomes, MYO5B; Arquitectura epitelial; Reciclaje de endosomas, MYO5B; Arquitectura epitelial; Reciclatge d'endosomes, Recycling endosomes regulate plasma membrane recycling. Recently, recycling endosome–associated proteins have been implicated in the positioning and orientation of the mitotic spindle and cytokinesis. Loss of MYO5B, encoding the recycling endosome–associated myosin Vb, is associated with tumor development and tissue architecture defects in the gastrointestinal tract. Whether loss of MYO5B expression affects mitosis is not known. Here, we demonstrate that loss of MYO5B expression delayed cytokinesis, perturbed mitotic spindle orientation, led to the misorientation of the plane of cell division during the course of mitosis, and resulted in the delamination of epithelial cells. Remarkably, the effects on spindle orientation, but not cytokinesis, were a direct consequence of physical hindrance by giant late endosomes, which were formed in a chloride channel–sensitive manner concomitant with a redistribution of chloride channels from the cell periphery to late endosomes upon loss of MYO5B. Rab7 availability was identified as a limiting factor for the development of giant late endosomes. In accordance, increasing rab7 availability corrected mitotic spindle misorientation and cell delamination in cells lacking MYO5B expression. In conclusion, we identified a novel role for MYO5B in the regulation of late endosome size control and identify the inability to control late endosome size as an unexpected novel mechanism underlying defects in cell division orientation and epithelial architecture., AD: Association for International Cancer Research (AICR13-0245), https://www.aicr.org AD: European Regional Development Fund (ERDF; PI16/00540 and AC15/00066), https://ec.europa.eu/regional_policy/en/funding/erdf AD: Spanish Association Against Cancer (AECC GCA15152966ARAN), https://www.uicc.org AD: the Instituto de Salud Carlos III, https://www.isciii.es/Paginas/Inicio.aspx IZ: The Dutch Research Council, Domain Applied and Engineering Sciences, https://www.nwo.nl/en JK: The Netherlands Organisation for Health Research and Development, 91111.006, https://www.zonmw.nl/en/ JK: The Dutch Research Council, 175-010-2009-023, https://www.nwo.nl/en CK: Chinese Scholarship Council, https://www.chinesescholarshipcouncil.com/ QL: Chinese Scholarship Council, https://www.chinesescholarshipcouncil.com/ YC: Chinese Scholarship Council, https://www.chinesescholarshipcouncil.com/